On March 21, 2025, Soligenix, Inc. (SNGX) announced financial results for 2024 and provided a business update. The company recently announced a publication in the journal COVID highlighting preclinical results showing that CiVax , a thermostabilized subunit vaccine against SARS-CoV-2, in combination with a primary adenovirus vaccine induced broader protection against COVID-19 variants in non-human primates than a 2-shot mRNA series. The company's ThermoVax platform has previously produced efficacious, thermostabilized vaccines for ricin toxin and filoviruses (Ebola, Marburg, etc.). The ability to produce a thermostabilized COVID-19 vaccine makes the use of a protein subunit vaccine competitive with other vaccine technologies, such as mRNA, that rely on cold-chain requirements.
